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Abstract
Introduction: Current prognostic gene expression profiles for breast cancer mainly reflect proliferation status and
are most useful in ER-positive cancers. Triple negative breast cancers (TNBC) are clinically heterogeneous and
prognostic markers and biology-based therapies are needed to better treat this disease.
Methods: We assembled Affymetrix gene expression data for 579 TNBC and performed unsupervised analysis to
define metagenes that distinguish molecular subsets within TNBC. We used n = 394 cases for discovery and n =
185 cases for validation. Sixteen metagenes emerged that identified basal-like, apocrine and claudin-low molecular
subtypes, or reflected various non-neoplastic cell populations, including immune cells, blood, adipocytes, stroma,
angiogenesis and inflammation within the cancer. The expressions of these metagenes were correlated with
survival and multivariate analysis was performed, including routine clinical and pathological variables.
Results: Seventy-three percent of TNBC displayed basal-like molecular subtype that correlated with high
histological grade and younger age. Survival of basal-like TNBC was not different from non basal-like TNBC. High
expression of immune cell metagenes was associated with good and high expression of inflammation and
angiogenesis-related metagenes were associated with poor prognosis. A ratio of high B-cell and low IL-8
metagenes identified 32% of TNBC with good prognosis (hazard ratio (HR) 0.37, 95% CI 0.22 to 0.61; P < 0.001) and
was the only significant predictor in multivariate analysis including routine clinicopathological variables.
Conclusions: We describe a ratio of high B-cell presence and low IL-8 activity as a powerful new prognostic
marker for TNBC. Inhibition of the IL-8 pathway also represents an attractive novel therapeutic target for this
disease.
Introduction
Different molecular subtypes of breast cancer have been
described [1]. The most profound effects on gene
expression profiles in breast cancer are related to estro-
gen (ER), and proliferation status, and to a lesser extent
to Human Epidermal Growth Factor Receptor 2 (HER2)
status. Not surprisingly, molecular classification and cur-
rent prognostic signatures mainly reflect these molecular
features [2]. However, substantial clinical and molecular
heterogeneity remains within current molecular subsets,
particularly among ER, progesterone (PgR) and HER2
receptor negative (that is, triple negative breast cancers,
TNBC [3]). Furthermore the relationship between clini-
cally defined TNBC and the gene expression profile-
based basal-like breast cancer subtype (BLBC) [4] is not
fully defined [5]. Some authors use these two terms
synonymously given the substantial overlap between the
two definitions [6,7]. However, immunohistochemical
and molecular profiling studies have shown that only a
subset of TNBC express the combination of basal cell
markers (for example, CK5 and CK14) that is required
for the molecular definition of this disease [5]. The
prognostic significance and therapeutic implications of
molecular heterogeneity within TNBC remains to be
established. From a clinical point of view, further
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prognostic markers and new treatments are needed [8].
The goal of this analysis was to assemble all currently
available TNBC gene expression datasets generated on
Affymetrix gene chips and search for molecular struc-
tures in the data to define gene expression-based subsets
within TNBC. We defined metagenes as the average
expression of groups of highly co-expressed genes in the
data without considering any clinical outcome variable.
These metagenes identified several molecular subsets
within TNBC, some with good prognosis even in the
absence of systemic therapy. Our results also suggest
possible new therapeutic strategies for TNBC. This
study represents the largest attempt to define clinically
important molecular subsets within TNBC [9].
Materials and methods
All analyses were performed according to the REporting
recommendations for tumour MARKer prognostic stu-
dies (REMARK) recommendations for prognostic and
tumor marker studies [10,11] and the respective guide-
lines to microarray-based studies for clinical outcomes
[12]. A respective diagram of the complete analytical
strategy and the flow of patients through the study,
including the number of patients included in each stage
of the analysis, is given in Additional file 1, Supplemen-
tary Figure S1. Tissue samples of invasive breast cancer
c a s e s( d a t a s e tF r a n k f u r t )w e r eo b t a i n e dw i t hI R B
approval and informed consent from consecutive
patients undergoing surgical resection between Decem-
ber 1996 and July 2007 at the Department of Gynecol-
ogy and Obstetrics at the Goethe-University in
Frankfurt. Gene expression data have been deposited
into the GEO database (accession number GSE31519).
Assembly of TNBC microarray data and definition of
metagenes
In order to facilitate pooling of data sets from different
l a b o r a t o r i e sw eo n l yu s e dd a t af r o mas i n g l ep l a t f o r m
(Affymetrix U133A and U133 Plus 2.0 chips) and
included only samples that were defined as triple nega-
tive based on the mRNA expression of ER, PgR, and
HER2 as previously described [13-15]. To obtain a large
enough sample size for discovery it was necessary to
pool several datasets. A major concern during this exer-
cise is the possible confounding effect of systematic
technical differences that exist between individual data-
sets. These could lead to false discovery during meta-
gene definition and could also weaken the power of
validation. We applied two different strategies to mini-
mize this problem. First, we selected only highly com-
parable datasets for discovery. We initially identified 579
TNBC from a total of 3,488 publicly available primary
breast cancer gene expression profiles representing 28
individual datasets (Additional file 2, Supplementary
T a b l eS 1 ) .W ee x c l u d e d1 3d a t a s e t sc o n t r i b u t i n g1 8 5
TNBC cases from the discovery cohort because they did
not fulfill our criteria of comparability of the microarray
data (for details see Additional file 4, Supplementary
Methods Section 1 and Additional file 1, Supplementary
Figure S2). The final discovery cohort to identify meta-
genes included 394 TNBC from 15 datasets (cohort-A).
The 185 samples excluded from discovery were retained
as a validation set (cohort-B) to assess correlations
between various metagenes and between metagenes and
clinical outcome (Additional file 1, Supplementary Fig-
ure S1). This strategy maximized the integrity of meta-
gene discovery at the cost of possibly reducing the
power of the validation study. The two cohorts did not
significantly differ with respect to age, tumor size and
histological grade. However, the validation cohort-B
contained a larger number of lymph node positive
patients and a higher proportion of fine needle aspira-
tion (FNA) samples. Follow-up data were available for
2,348 of the total 3,488 samples and 327 of the 579
TNBC samples. Since the number of patients with fol-
low-up in validation cohort B was too small (n =3 0o f
185) an additional independent validation cohort-C [16]
(n = 76) was included to assess the prognostic value of
the metagenes (Additional file 1, Supplementary Figure
S1). The patient characteristics of the discovery and vali-
dation cohorts are given in Table 1. For analysis of nor-
mal tissue a dataset from a benign breast was used
(Additional file 2, Supplementary Table S1).
Unsupervised analysis, without input of clinical vari-
ables, was performed to identify metagenes that were
defined as the arithmetical average expression of highly
correlated genes. Gene clusters were selected with either
a minimal membership of 10 genes and a minimal cor-
relation threshold of 0.7, or a minimum of 25 genes and
a correlation of 0.6, respectively (for details see Addi-
tional file 4, Supplementary Methods Section 2). We
also employed a screen to remove genes that showed
data-set bias. The dependence of the expression levels
of the metagene probesets on the dataset vector was
analyzed using the Kruskal-Wallis statistic (Additional
file 4, Supplementary Methods Section 3). Only Stroma
and Hemoglobin metagenes displayed a bias for FNA
samples that reflect frequent contamination of these
types of samples with blood and the lack of stromal ele-
ments compared to core needle or surgical biopsies
(Additional file 1, Supplementary Figure S3 and Addi-
tional file 4, Supplementary Methods). Therefore, these
two metagenes were analyzed only in surgical biopsies.
No systematic bias was observed between the U133A
and U133 Plus2.0 arrays, which differ only in the spatial
feature size of the probesets (for details see Additional
file 4, Supplementary Methods Section 4). Both
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used to classify subtypes of TNBC as given in Additional
file 4, Supplementary Methods Sections 8 and 9).
Survival analysis
Relapse free survival (RFS) was preferentially used as a
clinical endpoint for event free survival (EFS). Only if
RFS was not available in some datasets was it replaced
by distant metastasis free survival (DMFS). Details on
used endpoints, Kaplan-Meier and Cox regression analy-
sis are given in Additional file 4, Supplementary Meth-
ods Section 5. Optimized cutoffs for dichotomizing of
metagene scores to plot survival curves were derived
from the discovery cohort and were applied without
modification to the validation cohorts (Additional file 4,
Supplementary Methods Section 6). All P-values are
two-sided and 0.05 was considered as a significant
result. Analyses were performed using the R software
[17] and SPSS version 17.0 (SPSS Inc. Chicago, IL).
Results
Identification of subsets of TNBC based on metagene
expression profile
In our discovery cohort we identified 16 clusters of corre-
lated genes by unsupervised methods whose expression
values were averaged as metagenes (Figure 1). As
expected, no cluster of genes correlated with ER, PgR,
and HER2 status [4] were identified. In contrast the iden-
tified metagenes presented in Table 2 included the basal-
like phenotype [4], an apocrine/androgen receptor signal-
ing signature [18,19], five signatures related to different
types of immune cells [4,20-25], a stromal signature
[26,27], the claudin-CD24 signature [28,29], markers of
blood [30] and adipocytes [4], as well as an inflammatory
signature [31-33] and an angiogenesis signature [23,34].
These phenotypes corresponded to previously described
gene signatures that have also been used to define subsets
of TNBC in a recent smaller study [9]. The angiogenesis
signature (VEGF metagene) has been described very
recently as a “hypoxia signature” associated with poor
outcome and expressed in distant metastases [34]. As
shown in Figure 1, we observed the highest correlation
between different types of immune cell metagenes. Simi-
lar relationships between the metagenes were detected in
the validation cohort-B (Figure 1) and -C (Additional file
1, Supplementary Figure S4). The presence of B-lympho-
cytes in the tumor is the primary source of the expression
of the B-Cell metagene that is largely composed of
immunoglobulin genes [20,22]. In contrast, immunohis-
tochemical analyses of IL-8 expression and analysis of
Table 1 Clinical data of TNBC patients from the finding-cohort-A and the validation cohorts-B and -C
Parameter Status Finding cohort-A (n =
394)
Validation cohort-B (n =
185)
P-value
(Chi
2)
Bv sA
Validation cohort-C (n =
76)
P-value
(Chi
2)
Cv sA
Lymph node
status
LNN 240 36 44
Node pos. 68 60 < 0.001 32 0.001
n.a. 86 89 0
Age ≤ 40 yr 63 25 10
41 to 50 yr 91 41 17
51 to 60 yr 76 39 13
> 60 yr 79 35 0.87 36 0.003
n.a. 85 45 0
Tumor size ≤ 2c m 8 5 2 9 1 1
> 2 cm 224 122 0.068 62 0.035
n.a. 85 34 3
Histological
grade
grade 3 227 110 62
grade 1 and
2
82 46 0.57 14 0.18
n.a. 85 29 0
Biopsy method surgical 346 130 76
core 19 22 0
FNA 29 33 < 0.001 0 0.009
Five-year DFS no event 202 24 49
event 95 6 0.25 26 0.69
n.a. 97 155 1
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that carcinoma cells are the main source of the IL-8
metagene (Figure 2).
Relationship between TNBC and basal-like breast cancer
(BLBC)
We observed a clear bimodal distribution of the basal-
like metagene score among TNBC (Figure 3). This
bimodal distribution allows us to derive a cutoff to sepa-
rate cases into high and low expression groups by fitting
two normal distributions to the data (Figure 3). Accord-
ing to this cutoff, 72.8%, 73.0% and 69.7% of TNBC
were defined as BLBC in the discovery cohort-A, valida-
tion cohort-B, and validation cohort-C, respectively.
Table 3 compares the clinical characteristics of BLBC or
non-BLBC triple negative cancers the discovery cohort-
A. The positive association between high histological
grade (G3, P < 0.001), younger age (P =0 . 0 0 4 )a n d
BLBC were also observed in the validation cohort-C and
validation cohort-B, respectively (Additional file 2, Sup-
plementary Table S2).
In unsupervised clustering of the metagenes the basal-
like metagene clustered next to the apocrine metagene
but showed a strong inverse correlation (Figure 1). To
quantify the correlation between the basal-like metagene
and all other metagenes from Table 2 we used quartiles
of the respective metagenes. Additional file 2, Supple-
mentary Table S3 presents the six metagenes that dis-
played significant correlations with the BLBC phenotype
in both the discovery and validation cohorts. A positive
correlation was found between the BLBC phenotype and
the proliferation and angiogenesis (VEGF) metagenes. A
negative correlation was observed for the apocrine/
androgen receptor signaling and two immune system
related metagenes (MHC-2 and T-Cell metagenes), as
well as an adipocyte related signature.
Since we observed a negative correlation between the
basal-like metagene and potential markers of normal
breast tissue, such as the adipocyte metagene, we had to
exclude the possibility that we are only distinguishing
stroma-rich and stroma-poor samples. As shown in
Additional file 1, Supplementary Figure S5, when meta-
genes for proliferation, adipocytes and histones were
compared between BLBC, non-BLBC, and normal breast
samples it is clearly demonstrated that the non-BLBC
subtype is distinct from normal breast tissues in the
Validation cohort-B (n=185 TNBC) 
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Figure 1 Principal biological phenotypes identified as metagenes among TNBC. Heatmaps of expression values of the 16 metagenes
(upper panels) and the 355 individual Affymetrix probe sets (lower panels) are shown for the finding cohort (left panels, n = 394) and validation
cohort (right panels, n = 185). The dendrogram at the left presents the results from hierarchical clustering of the metagenes. Three major
clusters were observed representing (i) basal-like, apocrine, CLDN-CD24, proliferation, and adipocyte metagenes (ii) all five immune cell metagenes,
and (iii) the IL-8 and VEGF metagenes, when the hemoglobin and stroma metagenes were left out which display some dataset-bias (see
methods). In keeping with these three major phenotypes the samples were sorted according to (1.) Basal-like phenotype, (2.) low vs. high B-Cell
metagene, and (3.) the expression value of the IL-8 metagene. (The 355 individual Affymetrix probesets and the respective metagenes are listed
in the Additional file 4, Supplementary Methods).
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Page 4 of 12Table 2 Principal biological phenotypes identified as metagenes among TNBC
Biological component Metagene
name
Correlation within
metagene cluster
# of probesets in
metagene cluster
Key markers Reference
Basal-like phenotype Basal-like 0.61 37 KRT-5,-6, -14, -17, SOX10, SFRP1,
ELF5, EPHB3, GABRP
[4]
Apocrine/androgen
receptor signalling
Apocrine 0.67 27 AR, FOXA1 [18,19]
Immune system: [4,20,21,23-25]
￿ B-Cell B-Cell 0.87 48 IgG
￿ T-Cell T-Cell 0.84 27 TCR, LCK, ITK
￿ MHC class II MHC-2 0.83 14 HLA-DR, -DM, -DP, -DQ
￿ MHC class I MHC-1 0.84 17 HLA-A, -B, -C, -E, -F, -G
￿ Interferone response IFN 0.76 14 OAS1, OAS2, OAS3, MX1
Stroma* Stroma 0.83 47 Decorin, Osteonectin, Fibronectin,
COL5A1
[26,27]
Claudin-CD24 signature Claudin-
CD24
0.70 19 CLDN3, CLDN4, CD24, ELF3 [28,29]
Proliferation Proliferation 0.74 47 BUB1, CDC2, STK6, BIRC5, TOP2A, [35]
Blood * Hemoglobin
*
0.63 17 HBA1, HBA2, HBB [30]
Adipocytes Adipocyte 0.74 8 FABP4, PLIN, ADIPOQ, ADH1B [4]
Angiogenesis VEGF 0.57 7 VEGF, adrenomedullin, ANGPTL4 [34]
Inflammation IL-8 0.52 4 IL-8, CXCL1, CXCL2 [31,32]
HOXA gene cluster HOXA 0.52 8 HOXA-4, -5, -7, -9, -10, -11 [64]
Histone gene cluster Histone 0.69 19 Histones H2A, H2B [65]
* The Stroma and Hemoglobin metagenes displayed a bias between datasets related to different biopsy techniques (see Methods).
[AU Query: Please choose a title of no more than 15 words for Tables 3 and 4. All other information should be placed in a legend beneath each table. AU
Response: Done, additional information transferred into footnotes]
 
     
A  B 
Figure 2 Immunohistochemical analyses of the cellular source of expression of the B-Cell and IL-8 metagenes in TNBC. A) Detection of
B-lymphocytes by a CD20 antibody (red staining) in a triple negative breast cancer from the Frankfurt cohort with high expression of B-Cell and
IL-8 metagenes. B) An adjacent section of the same tumor as in (A) is stained with an IL-8 antibody demonstrating that carcinoma cells are the
source of IL-8 expression (red staining). Note the strong IL-8 staining in rod-like structures in the carcinoma cells. Further analyses using
antibodies specific for macrophages (CD68) also demonstrated that macrophages are not the cellular source of IL-8 expression in the tumor
(Additional file 1, Supplementary Figure S15).
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have been previously shown to be the most important
determinant of cancer vs normal signatures [35].
Furthermore, the strong bimodal distribution of the
basal-like metagene argues against the possibility that
this metagene is inversely describing the degree of con-
tamination with normal tissue which should rather
result in a continuous distribution. The non-BLBC
tumors in our TNBC dataset mainly represent samples
of the “molecular apocrine” type (16.5%), which demon-
strates the inverse bimodal distribution as the basal-like
metagene, and a relatively small group of “claudin-low”
tumors (6.3%). The mutual relationship of these three
metagenes is shown in Additional file 1, Supplementary
Figure S6.
Prognostic value of the different biological phenotypes in
TNBC
To assess the prognostic value of the metagenes, we
analyzed the event free survival of patients as a function
of metagene expression. The basal-like metagene had
no significant effect on survival (Additional file 1, Sup-
plementary Figure S7). In contrast, five other metagenes
including the IL-8, Histone, VEGF, B-Cell,a n dT-Cell
metagenes showed significant prognostic values when
considered as continuous variables in univariate analysis
(Additional file 2, Supplementary Table S4). In a step-
wise multivariate Cox regression analysis only three of
these, the IL-8, Histone,a n dt h eB-Cell metagenes,
remained significant (Additional file 2, Supplementary
Table S5). The IL-8 and Histone metagenes were posi-
tively correlated with one another in all data sets (see
Figure 1). The B-cell and IL-8 metagenes were asso-
ciated with prognosis but with an opposing direction.
Based on these observations, we derived a B-Cell /IL-8
metagene ratio as a prognostic index for TNBC. Figure
4A demonstrates that patients with a high expression of
the B-Cell and low expression of the IL8 metagene have
significantly better prognosis than other TNBC patients
(HR 0.37, 95% CI 0.22 to 0.61; P < 0.001). The five-year
event-free survival was 84 ± 4% for the good prognosis
group (n = 95) compared to 59 ± 4% for the rest of the
patients. In validation cohort B (n =3 0 ) ,t h e r ew a sa
non-significant trend for better survival for patients with
high B-cell low IL8 metagene expression (P = 0.3, Figure
4B). Since this cohort has limited power due to the
small sample size, we also tested the prognostic value
o nas e p a r a t ea n dl a r g e r( n = 75) validation cohort of
TNBC samples [16]. The B-cell/IL8 metagene ratio had
significant prognostic value in this second validation
cohort C, the hazard ratio (HR) was 0.26, (95% CI 0.10
to 0.68) and the five-year DFS was 78 ± 9% vs. 45 ± 8%,
(P = 0.003) (Figure 4C). The prognostic value was inde-
pendent of histological grade; Figure 4D, E shows
pooled data from all three cohorts to increase sample
size, (see also Additional file 1, Supplementary Figure S8
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Figure 3 Distribution of the expression of the basal-like
metagene among TNBC of cohort-A. The bimodal distribution of
the expression of the basal-like metagene among the 394 TNBC
samples in the finding cohort-A is shown. A mixture (black line) of
two normal gaussian distributions (blue and red lines) was fitted to
these data. The interception of the two gaussians was derived as a
cutoff (0.0014) for the definition of basal-like tumors. Similar results
were obtained for the validation cohorts-B, and -C, as well as from
all samples combined.
Table 3 Clinical parameters of TNBC with basal-like breast cancer (BLBC) or non-BLBC phenotype
Parameter Information available* Non-BLBC
(n = 107, 27.2%)
BLBC
(n = 287, 72.8%)
Total (n = 394) P-value
lymph node status n = 308 LNN 50 (64.9%) 190 (82.3%) 240
N1 27 (35.1%) 41 (17.7%) 68 0.002
Age 50 yrs n = 309 ≤ 50 yr 27 (34.6%) 124 (53.7%) 151
> 50 yr 51 (65.4%) 107 (46.3%) 158 0.004
Tumor size n = 309 ≤ 2 cm 16 (20.5%) 69 (29.9%) 85
> 2 cm 62 (79.5%) 162 (70.1%) 224 0.14
Histological grade n = 309 G3 45 (57.0%) 182 (79.1%) 227
G1&2 34 (43.0%) 48 (20.9%) 82 < 0.001
* Number of cases with available information on the specific parameter in the finding cohort-A
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of the B-cell/IL8 metagene ratio was observed both in
BLBC and non-BLBC TNBCs (P =0 . 0 0 1a n dP =0 . 0 0 6 ,
respectively; Additional file 1, Supplementary Figure S9).
The proportion of BLBC cases was similar in the Good
and Poor prognosis groups defined by the B-cell/IL8 meta-
gene ratio (75.2% and 71.8%, respectively; P = 0.54).
To assess a potential predictive value for sensitivity to
systemic adjuvant chemotherapy, the patients were stra-
tified by adjuvant treatment. In the discovery cohort,
186 patients received no adjuvant systemic treatment
and 81 patients received chemotherapy (mostly Cyclo-
phosphamide Methotrexate Fluorouracil; CMF)). Better
prognosis was observed for the high B-cell/low IL8
group in both untreated (P = 0.001) as well as che-
motherapy treated patients (P =0 . 0 5 ;n o ts h o w n ) .A
potential predictive value of the B-cell and IL8 meta-
genes was also analyzed in 191 patients with TNBC who
received neoadjuvant chemotherapy. We assembled this
cohort of samples with information on pathologically
complete response (pCR) from seven datasets. As shown
in Additional file 1, Supplementary Figure S10 the B-cell
metagene had a modest predictive value with an area
under the curve (AUC) of 0.606 consistent with our pre-
vious results [22]. The predictive value for the IL8 meta-
gene was smaller (AUC -0.552). Combining both
metagenes increased the AUC to 0.612 (95% CI 0.519 to
0.704; P = 0.018).
In multivariate Cox regression analysis, including
lymph node status, age, tumor size, and histological
grade, only the combined B-Cell/IL8-metagene score
showed strong independent prognostic value in both the
Figure 4 Prognostic value of the combined B-Cell/IL-8 metagenes among TNBC. Kaplan Meier analysis of event free survival of 297 TNBC
patients with follow up from the finding cohort A. Samples were stratified according to prognostic predictor of the combined B-Cell/IL-8
metagenes. “Good” refers to 95 samples with both high B-Cell and low IL-8 metagene expression whereas all other samples (n = 202) are
referred as “Poor”. A) Prognostic value of the B-Cell/IL8-metagene prognostic predictor in the 30 TNBC patients with follow up from the
validation cohort-B. Samples were stratified as in (A). B) Prognostic value of the B-Cell/IL8-metagene prognostic predictor in the 75 TNBC
patients with follow-up from the independent validation cohort-C. Samples were stratified as in (A). C) Prognostic value of the combined B-Cell/
IL-8 metagenes among the subset of high grade (G3) TNBC tumors from all three cohorts -A, -B, and -C (n = 186). Samples were stratified as in
(A). (Results from the individual cohorts are given in Additional file 1, Supplemental Figure S8). D) Prognostic value of the combined B-Cell/IL-8
metagenes among the subset of low to medium grade (G1 and G2) TNBC tumors from all three cohorts -A, -B, and -C (n = 77). Samples were
stratified as in (A). (Results from the individual cohorts are given in Additional file 1, Supplemental Figure S8).
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and in the second, larger validation cohort-C, (HR 0.21,
95% CI 0.07 to 0.62, P =0 . 0 0 5 ) .T h eo n l yo t h e rv a r i a b l e
with borderline statistical significance (HR 0.40; 95% CI
0.17 to 0.99, P = 0.046) was lymph node status in valida-
tion cohort-C (Table 4). However, even in univariate ana-
lyses the remaining clinical variables did not show a
significant prognostic value in the analyzed cohorts. This
might be attributed to the fact that most TNBC are usually
highly proliferating and grading is not as important for
prognosis in this subtype as it is in ER positive disease; in
addition, the power of our analysis may be limited to
detecting the modest effect of age and tumor size on prog-
nosis within this sample set. The inclusion of a term for
chemotherapeutic treatment in the multivariate analysis
further reduced the sample size to 213 patients in cohort-
A (no treatment information was available for patients
from validation cohort-B). Of these 213 patients only 37
were treated with chemotherapy. The combined B-Cell/
IL8-metagene score remained significant (P =0 . 0 0 1 )i n
the corresponding multivariate analysis (Additional file 2,
Supplementary Table S9A). Unexpectedly, chemotherapy
treatment was associated with a worse prognosis probably
due to chance or some form of selection bias to include
higher risk patients in these public data sets (Additional
file 2, Supplementary Table S9A). This selection bias is
consistent with a significant higher portion of node posi-
tive patients in the chemotherapy group (P = 0.001) and a
trend for a higher histological grade (P = 0.074; Additional
file 2, Supplementary Table S9B).
Relationship of the identified metagenes to known
prognostic signatures
The correlation of several published prognostic gene sig-
natures to the metagenes discovered within the pure
TNBC cohort was analyzed by hierarchical clustering
using the gene expression data from cohort-A (Addi-
tional file 4, Supplementary Methods Section 13). As
shown in Additional file 1, Supplementary Figure S11,
the “recurrence score” [36], “genomic grading index”
(GGI) [37], and the “wound response signature” [38]
display high correlation to the proliferation metagene.
On the other hand the “7-gene immune response (IR)
signature” [39], the “stroma derived prognostic predic-
tor” (SDPP) [40], and the “368 gene medullary breast
cancer signature” [16] were all highly correlated to
immune cell metagenes. The magnitude of the correla-
tion (R
2 = 0.4 to approximately 0.7) between the differ-
ent immune metagenes and the related signatures is at
the same high level as the correlation between genes
within other metagene clusters (R
2 =0 . 5t oa p p r o x i -
mately 0.7; Table 2). We demonstrated previously [22]
that even if the different immune metagenes can discri-
minate between distinct types of immune cells, the
actual infiltration of tumors generally represents a mix-
ture of these different immune cells. In most cases, the
differences in the proportions in this mixture are smal-
ler than the global differences in lymphocyte infiltration
between individual tumors. Therefore, different immune
signatures often carry redundant prognostic information
and can replace each other. In contrast to the immune
cell metagenes no correlation between the IL8 metagene
and other signatures were observed.
Discussion
It has been suggested that TNBC represent a group of
several molecularly [3] and clinically [41,42] distinct dis-
ease subtypes. We used gene expression data of a cohort
of 394 TNBC to identify molecular subsets within this
tumor type. The definition of TNBC was based on gene
Table 4 Multivariate analysis of EFS according to standard parameters and the combined B-Cell/IL8-metagene in TNBC
Finding cohort A* Validation cohort C*
Variable No. of
patients
†
Hazard
ratio
95% CI P-
value
‡
No. of
patients
§
Hazard
ratio
95% CI P-
value
‡
Lymph node
status
LNN vs N1 210 vs 27 0.59 0.31 to
1.12
0.10 43 vs 29 0.40 0.17 to
0.99
0.046
Age > 50 vs ≤ 50 113 vs 124 0.75 0.48 to
1.17
0.21 48 vs 24 1.68 0.65 to
4.38
0.29
Tumor size ≤ 2c mv s>2
cm
71 vs 166 0.73 0.44 to
1.21
0.22 11 vs 61 0.99 0.28 to
3.42
0.98
Histological
grading
G3 vs G1 and 2 166 vs 71 1.11 0.68 to
1.81
0.68 59 vs 13 0.53 0.22 to
1.29
0.16
B-Cell/IL8-
Signature
Good vs Poor
|| 78 vs 159 0.38 0.22 to
0.67
0.001 29 vs 43 0.21 0.07 to
0.62
0.005
* Results from multivariate Cox analysis of event free survival in the TNBC finding cohort A and validation cohort C are presented.
† information on all parameters was available for 237 of the 297 TNBC samples with follow up data from the finding cohort A.
‡ Significant P-values are given in bold
§ information on all parameters was available for 72 of the 76 TNBC samples with follow up data from the validation cohort C.
|| “Good“ refers to high B-Cell metagene together with low IL8 metagene expression compared to all the remaining samples referred as “Poor“.
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used in the clinic. This might be a caveat but holds the
promise that samples erroneously characterized as
receptor-negative by immunohistochemistry do not
introduce noise into our analysis. We identified 16
metagenes associated with several distinct biological
processes that showed variable expression across TNBC
(Table 2). Some of the metagenes seem to point to the
distinct origins of these cancers [43,44]. These include
the basal-like [4], the apocrine [18,19], and the claudin-
low [28,29] subtypes of TNBC. Other metagenes were
related to non-neoplastic cellular constituents of the
tumor microenvironment including stroma [26,27],
blood cell [30] and adipocytes [4], as well as signatures
for angiogenesis [23,34] and inflammation [31-33]. Five
metagenes appear to reflect the variable presence of
immune cells and may contribute to the clinical beha-
vior of the cancer [4,20-25,27,45] (Table 2).
Kreike et al. [9] detected similar metagenes among 97
TNBC analysed with a different microarray platform.
That study suggested that the TNBC clinical phenotype
can be equated to the BLBC molecular class determined
by the centroid method [46] since 95% of the TNBCs
were assigned basal-like molecular class [47]. However,
the centroid method is highly susceptible to the compo-
sition of the dataset that is used to define the reference
centroids [48] and variants of the method can lead to
different results [49]. Bertucci et al. [50] identified only
71% of their 172 TNBC cases as basal-like when using a
slightly different version of the centroid method for
molecular classification. When we applied different ver-
sions of the centroid method to 1,364 breast cancers,
65% to 90% of the TNBC samples (n = 172) were
assigned to the basal-like class depending on the
method used (Additional file 2, Supplementary Table
S6). In this paper we took a different approach and first
identified metagenes and used these metagenes to define
molecular subsets among TNBC. One of our metagenes
corresponded closely to the gene signatures that are
used to define BLBC in the centroid based methods.
Our results indicate that BLBC defined based on the
basal-like metagene expression represent around 73% of
TNBC (Table 3 and Additional file 2, Supplementary
Table S2).
The proportion of BLBC among TNBC in our study is
similar to results from an immunohistochemical study
by Rakha et al. [7] that defined BLBC by the expression
of CK5/6, CK14, CK17 or EGFR. These authors
observed a worse survival of the 165 patients with BLBC
compared to the remaining 67 TNBC cases, which
expressed none of these markers. However, we did not
detect differences in the prognosis of BLBC and non-
BLBC type triple negative cancers (Additional file 1,
Supplementary Figure S7). In the study by Rakha et al.
the prognostic effect was mainly confined to 103
untreated patients. Still, even when we analyzed
untreated patients (n = 186) separately, we detected no
prognostic value of the BLBC phenotype (not shown).
Our results are also contrary to the immunohistochem-
ical study of Cheang et al. [51], which used CK5/6 and
EGFR antibodies for TNBC stratification. They also
observed a worse prognosis of 336 BLBC TNBC com-
pared to 303 non-BLBC TNBC. However, our study is
not directly comparable to these prior reports because
our definition of BLBC is fundamentally different from
the IHC-based methods. Our results are in line with
several other genomic profiling studies that reported
limited prognostic value for the BLBC molecular class
among clinically triple negative cancers [18,19,50].
We observed strong prognostic value for several of the
other metagenes (Additional file 2, Supplementary Table
S4). An improved prognosis was observed for patients
with tumors displaying high expression of immune sys-
tem related metagenes which supports recent reports
[20,23-25,27,39,40,52,53]. An association with decreased
survival was observed for high expression of inflamma-
tion (IL-8), an angiogenesis/hypoxia signature (VEGF)
[34], and histone-related metagenes (Additional file 2,
Supplementary Table S4 and Figure 1). A simple combi-
nation of high B-Cell and low IL8 metagene expression
identifies a subset of TNBC patients (32% of all) with a
favorable prognosis and a five-year event-free survival of
84%. In multivariate analysis, only this metagene ratio
and lymph node status were significant predictors of
TNBC in our cohort of patients (Table 4 and Figure 4D,
E). Other known prognostic factors in breast cancer,
such as age, tumor size and histological grade, were not
significant in our cohorts, even in univariate analysis.
Most TNBC are high grade and, therefore, grade is not
as important for prognosis in this subtype as it is in ER
positive disease. TNBCs are also often associated with
younger age but the impact of age and tumor size for
prognosis within this subtype is not yet fully clear. Still
it cannot be excluded that a bias in our cohort is the
reason for the lack of the significance of these factors.
Our analyses of neoadjuvant treated TNBC samples sug-
gest modest predictive value of the B-cell/IL8 metagene
ratio for currently used chemotherapies [22,54] (Addi-
tional file 1, Supplementary Figure S10). We also
observed a pure prognostic value in untreated patients
of finding the cohort in line with other reports on B-cell
metagene [24,27]. Treatment information on the sam-
ples from the validation cohort was not available.
Our observation is important since every currently
available genomic prognostic signature, (for example,
the 70-gene profile [55], Recurrence Score [36], Geno-
mic Grading Index [37]), assigns poor prognostic risk
status to all TNBC samples despite their variable
Rody et al. Breast Cancer Research 2011, 13:R97
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Page 9 of 12outcome [56-58]. One of these signatures, the Rotter-
dam-76-gene prognostic signature [59], was developed
in a way to allow prognostic stratification of ER-negative
cancers. However, similar to other reports [9] we were
n o ta b l et od e m o n s t r a t eap r o g n o s t i cv a l u ef o rt h i ss i g -
nature (Additional file 1, Supplementary Figure S12).
We used an unsupervised class discovery approach to
first identify the main molecular subtypes within the
data and then assess the prognostic differences between
the molecular subsets. Interestingly, when we performed
an independent supervised analysis that compared
TNBC cases with or without recurrence, we also identi-
fied IL-8 as the top ranked gene associated with poor
prognosis (Additional file 1, Supplementary Figure S13
and Additional file 2, Supplementary Table S8). How-
ever, gene signatures obtained through supervised analy-
sis were not superior to the molecular structure based
prognostic predictions in validation (Additional file 1,
S u p p l e m e n t a r yF i g u r eS 1 4 ) .I na d d i t i o n ,t h eb i o l o g i c a l
interpretation of the empirically derived prognostic sig-
nature is more difficult than the interpretation of meta-
genes. In summary, we performed the largest
unsupervised analysis of pooled gene expression data
from TNBC. We describe a new prognostic signature
for these cancers that identify about one-third of TNBC
as relatively low risk for recurrence. These cancers are
characterized by high B-cell and low IL-8 metagene
expression and have about 84% recurrence-free survival
at five-years. Whereas, this may not be sufficiently high
to forego adjuvant chemotherapy, these observations
pave the way to develop a clinically useful multivariate
prognostic model for TNBC. A combined, prognostic
score, including clinical variables, such as nodal status
and perhaps tumor size, and molecular variables, such
as optimized B-cell and IL-8 metagenes (measured by
an RT-PCR or array-based method), may identify
patients with very low risk of recurrence even with ER-,
PgR- and HER2-negative breast cancer. Equally impor-
tant, the prognostic importance of B-cells and the nega-
tive impact of IL-8 suggest potential novel therapeutic
strategies for TNBC that can be tested in the clinic
[31,32]. It could allow the selection of those patients
who could profit most from novel immune stimulating
drugs like anti-CTLA-4 antibodies that have shown pro-
mise in melanoma [60,61]. IL8 could also directly
increase the survival of breast cancer stem cells after
chemotherapy [62], which can be blocked with IL8
directed drugs [63]. Such an effect might explain the tri-
ple negative paradox with high relapse rates despite a
good initial response to chemotherapy.
Conclusions
In the largest and most comprehensive analysis of all
available gene expression data in TNBC, we first
identified structures in the molecular data without con-
sidering any clinical outcome. Subsequently, these mole-
cular phenotypes were correlated with survival in
multivariate analysis, including routine clinical and
pathological variables. Our most important observation
is that a high B-cell presence and low IL-8 activity iden-
tifies a good prognosis group, even in the absence of
systemic therapy, among TNBC. These observations
directly point to therapeutic interventions, such as the
inhibition of the IL-8 pathway and activation of the
immune system in the tumor microenvironment that
could benefit patients with this disease.
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